Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in china. Nature. 2020;579:265–269. doi:10.1021/acs.biochem.0c00160
   PubMed Web of Science ®Google Scholar
• The Lancet Infectious Diseases. Covid-19, a pandemic or not? Lancet Infect Dis. 2020;20(4):383.
   Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (il-1 and il-6) and lung inflammation by coronavirus-19 (covi-19 or sars-cov-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327–331.
   PubMed Web of Science ®Google Scholar
• Conti P, Caraffa A, Gallenga CE, et al. Il-1 induces throboxane-a2 (txa2) in covid-19 causing inflammation and micro-thrombi: inhibitory effect of the il-1 receptor antagonist (il-1ra). J Biol Regul Homeost Agents. 2020;34:1623–1627.
   PubMed Web of Science ®Google Scholar
• Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34:9–14.
   PubMed Web of Science ®Google Scholar
• Sun J, He WT, Wang L, et al. Covid-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26:483–495. doi:10.1016/j.molmed.2020.02.008
   PubMed Web of Science ®Google Scholar
• Vellingiri B, Jayaramayya K, Iyer M, et al. Covid-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277. doi:10.1016/j.scitotenv.2020.138277
   PubMed Web of Science ®Google Scholar
• Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira M. Liquorice (glycyrrhiza glabra): a phytochemical and pharmacological review. Phytother Res. 2018;32:2323–2339. doi:10.1002/ptr.6178
   PubMedGoogle Scholar
• Oo A, Teoh BT, Sam SS, Bakar SA, Zandi K. Baicalein and baicalin as zika virus inhibitors. Arch Virol. 2019;164:585–593. doi:10.1007/s00705-018-4083-4
   PubMed Web of Science ®Google Scholar
• Huh J, Song JH, Kim SR, et al. Lignan dimers from forsythia viridissima roots and their antiviral effects. J Nat Prod. 2019;82:232–238. doi:10.1021/acs.jnatprod.8b00590
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Y, He D, et al. Natural oral anticancer medication in small ethanol nanosomes coated with a natural alkaline polysaccharide. ACS Appl Mater Interfaces. 2020;12:16159–16167. doi:10.1021/acsami.0c02788
   PubMedGoogle Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro. Cell Res. 2020;30:269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Morris-Natschke SL, Cheng YY, Lee KH, Li RT. Development of anti-influenza agents from natural products. Med Res Rev. 2020;40:2290–2338. doi:10.1002/med.21707
   PubMed Web of Science ®Google Scholar
• Visser LJ, Aloise C, Swatek KN, et al. Dissecting distinct proteolytic activities of fmdv lpro implicates cleavage and degradation of rlr signaling proteins, not its deisgylase/dub activity, in type i interferon suppression. PLoS Pathog. 2020;16:e1008702. doi:10.1371/journal.ppat.1008702
   PubMedGoogle Scholar
• Tiwari V, Beer JC, Sankaranarayanan NV, Swanson-Mungerson M, Desai UR. Discovering small-molecule therapeutics against sars-cov-2. Drug Discov Today. 2020;25:1535–1544. doi:10.1016/j.drudis.2020.06.017
   PubMed Web of Science ®Google Scholar
• Sinokrot H, Smerat T, Najjar A, Karaman R. Advanced prodrug strategies in nucleoside and non-nucleoside antiviral agents: a review of the recent five years. Molecules. 2017;22:1736.
   PubMedGoogle Scholar
• Gu J, Huang Y, Yan Z, et al. Biomimetic membrane-structured nanovesicles carrying a supramolecular enzyme to cure lung cancer. ACS Appl Mater Interfaces. 2020;12:31112–31123. doi:10.1021/acsami.0c06207
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y, Xie J, et al. Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. Nanoscale. 2020;12:15222–15235. doi:10.1039/D0NR02651D
   PubMedGoogle Scholar
• Goodarzi N, Barazesh Morgani A, Abrahamsson B, et al. Biowaiver monographs for immediate release solid oral dosage forms: ribavirin. J Pharm Sci. 2016;105:1362–1369. doi:10.1016/j.xphs.2016.01.017
   PubMedGoogle Scholar
• Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian h5n1 and pandemic 2009 a/h1n1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet. 2010;49:741–765. doi:10.2165/11534730-000000000-00000
   PubMed Web of Science ®Google Scholar
• Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. The influence of donor and reservoir additives on caco-2 permeability and secretory transport of hiv protease inhibitors and other lipophilic compounds. Pharm Res. 2000;17:1175–1180. doi:10.1023/A:1026402410783
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Jiang Q, Chi F, Liu Q, Zhang T. The delivery of arbidol by salt engineering: synthesis, physicochemical properties and pharmacokinetics. Drug Dev Ind Pharm. 2016;43:151–159. doi:10.1080/03639045.2016.1225755
   PubMedGoogle Scholar
• Yang J, Li K, He D, et al. Toward a better understanding of metabolic and pharmacokinetic characteristics of low-solubility, low-permeability natural medicines. Drug Metab Rev. 2020;52:19–43. doi:10.1080/03602532.2020.1714646
   PubMedGoogle Scholar
• Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antiviral Res. 2018;154:66–86.
   PubMed Web of Science ®Google Scholar
• Volpe DA. Advances in cell-based permeability assays to screen drugs for intestinal absorption. Expert Opin Drug Discov. 2020;15:539–549. doi:10.1080/17460441.2020.1735347
   PubMed Web of Science ®Google Scholar
• Babadi D, Dadashzadeh S, Osouli M, Daryabari MS, Haeri A. Nanoformulation strategies for improving intestinal permeability of drugs: a more precise look at permeability assessment methods and pharmacokinetic properties changes. J Control Release. 2020;321:669–709. doi:10.1016/j.jconrel.2020.02.041
   PubMed Web of Science ®Google Scholar
• Zi P, Zhang C, Ju C, et al. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - soluplus. Eur J Pharm Sci. 2019;134:233–245. doi:10.1016/j.ejps.2019.04.022
   PubMed Web of Science ®Google Scholar
• Ahire E, Thakkar S, Darshanwad M, Misra M. Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications. Acta Pharm Sin B. 2018;8:733–755. doi:10.1016/j.apsb.2018.07.011
   PubMed Web of Science ®Google Scholar
• Varela-Garcia A, Concheiro A, Alvarez-Lorenzo C. Soluplus micelles for acyclovir ocular delivery: formulation and cornea and sclera permeability. Int J Pharm. 2018;552:39–47. doi:10.1016/j.ijpharm.2018.09.053
   PubMed Web of Science ®Google Scholar
• Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018;15:93–114. doi:10.1080/17425247.2017.1360863
   PubMed Web of Science ®Google Scholar
• Dhore PW, Dave VS, Saoji SD, Bobde YS, Mack C, Raut NA. Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions. Pharm Dev Technol. 2016;22:90–102. doi:10.1080/10837450.2016.1193193
   PubMedGoogle Scholar
• Huang Y, Dai WG. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B. 2014;4:18–25. doi:10.1016/j.apsb.2013.11.001
   PubMed Web of Science ®Google Scholar
• Adeoye O, Conceicao J, Serra PA, et al. Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: in silico prediction; effects of derivatization, molar ratio and preparation method. Carbohydr Polym. 2020;227:115287. doi:10.1016/j.carbpol.2019.115287
   PubMed Web of Science ®Google Scholar
• Conceicao J, Adeoye O, Cabral-Marques HM, Lobo JMS. Cyclodextrins as excipients in tablet formulations. Drug Discov Today. 2018;23:1274–1284. doi:10.1016/j.drudis.2018.04.009
   PubMed Web of Science ®Google Scholar
• Karakucuk A, Teksin ZS, Eroglu H, Celebi N. Evaluation of improved oral bioavailability of ritonavir nanosuspension. Eur J Pharm Sci. 2019;131:153–158. doi:10.1016/j.ejps.2019.02.028
   PubMed Web of Science ®Google Scholar
• Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24:3. doi:10.1186/s40824-020-0184-8
   PubMedGoogle Scholar
• Deshmukh A, Kulkarni S. Solid self-microemulsifying drug delivery system of ritonavir. Drug Dev Ind Pharm. 2014;40:477–487. doi:10.3109/03639045.2013.768632
   PubMed Web of Science ®Google Scholar
• Vithani K, Jannin V, Pouton CW, Boyd BJ. Colloidal aspects of dispersion and digestion of self-dispersing lipid-based formulations for poorly water-soluble drugs. Adv Drug Deliv Rev. 2019;142:16–34. doi:10.1016/j.addr.2019.01.008
   PubMed Web of Science ®Google Scholar
• Kubbinga M, Augustijns P, García MA, et al. The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. Eur J Pharm Biopharm. 2019;136:147–155. doi:10.1016/j.ejpb.2019.01.021
   PubMedGoogle Scholar
• Wan S, He D, Yuan Y, Yan Z, Zhang X, Zhang J. Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase. Colloids Surf B Biointerfaces. 2016;143:278–284. doi:10.1016/j.colsurfb.2016.03.046
   PubMed Web of Science ®Google Scholar
• Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci. 2011;100:3186–3195. doi:10.1002/jps.22540
   PubMed Web of Science ®Google Scholar
• Incecayir T, Sun J, Tsume Y, et al. Carrier-mediated prodrug uptake to improve the oral bioavailability of polar drugs: an application to an oseltamivir analogue. J Pharm Sci. 2016;105:925–934. doi:10.1016/j.xphs.2015.11.036
   PubMedGoogle Scholar
• Gualdesi MS, Brinon MC, Quevedo MA. Intestinal permeability of lamivudine (3tc) and two novel 3tc prodrugs. Experimental and theoretical analyses. Eur J Pharm Sci. 2012;47:965–978. doi:10.1016/j.ejps.2012.10.002
   PubMedGoogle Scholar
• Zhou Y, Zhang M, He D, et al. Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes. Sci Rep. 2016;6:20136. doi:10.1038/srep20136
   Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21:1–20. doi:10.1016/j.cld.2016.08.001
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu S, Hu X, et al. Improved delivery of natural alkaloids into lung cancer through woody oil-based emulsive nanosystems. Drug Deliv. 2018;25:1426–1437. doi:10.1080/10717544.2018.1474970
   PubMed Web of Science ®Google Scholar
• Afsar NA, Bruckmueller H, Werk AN, Nisar MK, Ahmad HR, Cascorbi I. Implications of genetic variation of common drug metabolizing enzymes and abc transporters among the pakistani population. Sci Rep. 2019;9:7323. doi:10.1038/s41598-019-43736-z
   PubMedGoogle Scholar
• van Nuland M, Rosing H, Huitema ADR, Beijnen JH. Predictive value of microdose pharmacokinetics. Clin Pharmacokinet. 2019;58:1221–1236. doi:10.1007/s40262-019-00769-x
   PubMed Web of Science ®Google Scholar
• Eyer L, Nencka R, de Clercq E, Seley-Radtke K, Ruzek D. Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antivir Chem Chemother. 2018;26:2040206618761299. doi:10.1177/2040206618761299
   Google Scholar
• Urtishak KA, Wang LS, Culjkovic-Kraljacic B, et al. Targeting eif4e signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019;38:2241–2262. doi:10.1038/s41388-018-0567-7
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule gs-5734 against ebola virus in rhesus monkeys. Nature. 2016;531:381–385. doi:10.1038/nature17180
   PubMed Web of Science ®Google Scholar
• Huchting J, Vanderlinden E, Van Berwaer R, Meier C, Naesens L. Cell line-dependent activation and antiviral activity of t-1105, the non-fluorinated analogue of t-705 (favipiravir). Antiviral Res. 2019;167:1–5. doi:10.1016/j.antiviral.2019.04.002
   PubMed Web of Science ®Google Scholar
• Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. Pharmgkb summary. Pharmacogenet Genomics. 2012;22:891–894. doi:10.1097/FPC.0b013e32835879a8
   PubMed Web of Science ®Google Scholar
• Halling Folkmar Andersen A, Tolstrup M. The potential of long-acting, tissue-targeted synthetic nanotherapy for delivery of antiviral therapy against hiv infection. Viruses. 2020;12:412. doi:10.3390/v12040412
   PubMedGoogle Scholar
• Ray AS, Vela JE, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis b agent adefovir in hepatic cells. Biochem Pharmacol. 2004;68:1825–1831. doi:10.1016/j.bcp.2004.07.010
   PubMedGoogle Scholar
• Murata K, Tsukuda S, Suizu F, et al. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis b virus infection. Hepatology. 2020;71:1533–1545. doi:10.1002/hep.30956
   PubMedGoogle Scholar
• Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for sars-cov-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;59:659–669. doi:10.1007/s40262-020-00891-1
   PubMedGoogle Scholar
• Kraft JC, McConnachie LA, Koehn J, et al. Mechanism-based pharmacokinetic (mbpk) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-hiv drug combination nanoparticle formulation. J Control Release. 2018;275:229–241. doi:10.1016/j.jconrel.2018.02.003
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen B, Lei Z, et al. Synthesis and biological evaluation of nh2-sulfonyl oseltamivir analogues as influenza neuraminidase inhibitors. Molecules. 2019;24:2176. doi:10.3390/molecules24112176
   PubMedGoogle Scholar
• Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, et al. Arbidol and other low-molecular-weight drugs that inhibit lassa and ebola viruses. J Virol. 2019;93. doi:10.1128/JVI.02185-18
   PubMed Web of Science ®Google Scholar
• Kaspera R, Kirby BJ, Sahele T, et al. Investigating the contribution of cyp2j2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol. 2014;91:109–118. doi:10.1016/j.bcp.2014.06.020
   PubMed Web of Science ®Google Scholar
• Prasse C, Wagner M, Schulz R, Ternes TA. Oxidation of the antiviral drug acyclovir and its biodegradation product carboxy-acyclovir with ozone: kinetics and identification of oxidation products. Environ Sci Technol. 2012;46:2169–2178. doi:10.1021/es203712z
   PubMed Web of Science ®Google Scholar
• Nayar U, Sadek J, Reichel J, et al. Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies. J Clin Invest. 2017;127:2066–2080. doi:10.1172/JCI83936
   PubMedGoogle Scholar
• Fang -Z-Z, Tosh DK, Tanaka N, et al. Metabolic mapping of a3 adenosine receptor agonist mrs5980. Biochem Pharmacol. 2015;97:215–223. doi:10.1016/j.bcp.2015.07.007
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: an open-label, randomised, Phase 2 trial. Lancet. 2020;395:1695–1704. doi:10.1016/S0140-6736(20)31042-4
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382:2327–2336. doi:10.1056/NEJMoa2007016
   PubMed Web of Science ®Google Scholar
• Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for covid-19. Crit Care. 2020;24:413. doi:10.1186/s13054-020-03137-5
   PubMedGoogle Scholar
• Li X, Wang Y, Agostinis P, et al. Is hydroxychloroquine beneficial for covid-19 patients? Cell Death Dis. 2020;11:512. doi:10.1038/s41419-020-2721-8
   PubMed Web of Science ®Google Scholar
• Hazafa A, Ur-Rahman K, Haq IU, et al. The broad-spectrum antiviral recommendations for drug discovery against covid-19. Drug Metab Rev. 2020;52:408–424. doi:10.1080/03602532.2020.1770782
   PubMed Web of Science ®Google Scholar
• Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning covid-19. J Med Virol. 2020;92:740–746. doi:10.1002/jmv.25798
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits rna-dependent rna polymerase from middle east respiratory syndrome coronavirus. J Biol Chem. 2020;295:4773–4779. doi:10.1074/jbc.AC120.013056
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for covid-19: an open-label control study. Engineering (Beijing). 20206(10):1192–1198. doi:10.1016/j.eng.2020.03.007
   Google Scholar
• Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for covid-19? Int J Antimicrob Agents. 2020;55:105938. doi:10.1016/j.ijantimicag.2020.105938
   PubMed Web of Science ®Google Scholar
• Nutho B, Mahalapbutr P, Hengphasatporn K, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry. 2020;59:1769–1779.
   PubMed Web of Science ®Google Scholar
• Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of sars-cov-2 in vitro. Cell Discov. 2020;6:28. doi:10.1038/s41421-020-0169-8
   PubMed Web of Science ®Google Scholar
• Bi Y, Wong G, Liu Y, Liu L, Gao GF, Shi Y. Ribavirin is effective against drug-resistant h7n9 influenza virus infections. Protein Cell. 2016;7:611–614. doi:10.1007/s13238-016-0287-0
   PubMedGoogle Scholar
• Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis c virus activity of 2’-c-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother. 2006;50:3444–3446.
   PubMed Web of Science ®Google Scholar
• Mirabelli C, Jaspers M, Boon M, et al. Differential antiviral activities of respiratory syncytial virus (rsv) inhibitors in human airway epithelium. J Antimicrob Chemother. 2018;73:1823–1829. doi:10.1093/jac/dky089
   PubMed Web of Science ®Google Scholar
• Oestereich L, Rieger T, Ludtke A, et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever. J Infect Dis. 2016;213:934–938.
   PubMed Web of Science ®Google Scholar
• Oestereich L, Rieger T, Neumann M, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and t-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis. 2014;8:e2804. doi:10.1371/journal.pntd.0002804
   PubMed Web of Science ®Google Scholar
• Franco EJ, Rodriquez JL, Pomeroy JJ, Hanrahan KC, Brown AN. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antivir Chem Chemother. 2018;26:2040206618807580. doi:10.1177/2040206618807580
   Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against mers-cov. Nat Commun. 2020;11:222. doi:10.1038/s41467-019-13940-6
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221–e00218. doi:10.1128/mBio.00221-18
   PubMed Web of Science ®Google Scholar
• Frezza C, Grelli S, Federico M, Marino-Merlo F, Mastino A, Macchi B. Testing anti-hiv activity of antiretroviral agents in vitro using flow cytometry analysis of cem-gfp cells infected with transfection-derived hiv-1 nl4-3. J Med Virol. 2016;88:979–986. doi:10.1002/jmv.24418
   PubMedGoogle Scholar
• Liu X, Xu Z, Hou C, et al. Inhibition of hepatitis b virus replication by targeting ribonucleotide reductase m2 protein. Biochem Pharmacol. 2016;103:118–128. doi:10.1016/j.bcp.2016.01.003
   PubMed Web of Science ®Google Scholar
• Wiemer AJ, Wiemer DF. Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top Curr Chem. 2015;360:115–160.
   PubMed Web of Science ®Google Scholar
• Charlton MR, Alam A, Shukla A, et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis b virus infection in asia. J Gastroenterol. 2020;55:811–823. doi:10.1007/s00535-020-01698-4
   PubMed Web of Science ®Google Scholar
• Michaelis M, Kleinschmidt MC, Bojkova D, Rabenau HF, Wass MN, Cinatl J. Omeprazole increases the efficacy of acyclovir against herpes simplex virus type 1 and 2. Front Microbiol. 2019;10:2790. doi:10.3389/fmicb.2019.02790
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of sars coronavirus infection and spread. Virol J. 2005;2:69. doi:10.1186/1743-422X-2-69
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an fda-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875–4884. doi:10.1128/AAC.03011-14
   PubMed Web of Science ®Google Scholar
• Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits zika virus infection in different cell models. Viruses. 2016;8:322.
   PubMed Web of Science ®Google Scholar
• Shin JS, Ku KB, Jang Y, et al. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. J Microbiol. 2017;55:979–983.
   PubMedGoogle Scholar
• Du Q, Gu Z, Leneva I, et al. The antiviral activity of arbidol hydrochloride against herpes simplex virus type ii (hsv-2) in a mouse model of vaginitis. Int Immunopharmacol. 2019;68:58–67.
   PubMedGoogle Scholar
• Wang Y, Ding Y, Yang C, et al. Inhibition of the infectivity and inflammatory response of influenza virus by arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed Pharmacother. 2017;91:393–401. doi:10.1016/j.biopha.2017.04.091
   PubMed Web of Science ®Google Scholar
• Pecheur EI, Borisevich V, Halfmann P, et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol. 2016;90:3086–3092. doi:10.1128/JVI.02077-15
   PubMed Web of Science ®Google Scholar
• Wang PC, Chiu DC, Jan JT, et al. Peramivir conjugates as orally available agents against influenza h275y mutant. Eur J Med Chem. 2018;145:224–234. doi:10.1016/j.ejmech.2017.12.072
   PubMedGoogle Scholar
• Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase pa subunit. Antiviral Res. 2018;160:109–117. doi:10.1016/j.antiviral.2018.10.008
   PubMed Web of Science ®Google Scholar
• Bowman LJ, Melaragno JI, Brennan DC. Letermovir for the management of cytomegalovirus infection. Expert Opin Investig Drugs. 2017;26:235–241. doi:10.1080/13543784.2017.1274733
   PubMed Web of Science ®Google Scholar
• Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14:397–412. doi:10.1080/17460441.2019.1581171
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral gs-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653. doi:10.1126/scitranslmed.aal3653
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (t-705), a broad spectrum inhibitor of viral rna polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93:449–463. doi:10.2183/pjab.93.027
   PubMed Web of Science ®Google Scholar
• Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against sars-cov-2 infection (covid-19): a role for iron homeostasis? Pharmacol Res. 2020;158:104904. doi:10.1016/j.phrs.2020.104904
   PubMed Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with lpv/r versus lpv/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81:e1–e5. doi:10.1016/j.jinf.2020.03.002
   PubMed Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against sars-cov-2 and covid-19. Pharmacol Res. 2020;157:104859. doi:10.1016/j.phrs.2020.104859
   PubMed Web of Science ®Google Scholar
• Zannella A, Marignani M, Begini P. Hematological malignancies and hbv reactivation risk: suggestions for clinical management. Viruses. 2019;11:858. doi:10.3390/v11090858
   PubMedGoogle Scholar
• Morandi E, Tanasescu R, Tarlinton RE, Constantin-Teodosiu D, Gran B. Do antiretroviral drugs protect from multiple sclerosis by inhibiting expression of ms-associated retrovirus? Front Immunol. 2018;9:3092. doi:10.3389/fimmu.2018.03092
   PubMed Web of Science ®Google Scholar
• Quercia R, Perno CF, Koteff J, et al. Twenty-five years of lamivudine: current and future use for the treatment of hiv-1 infection. J Acquir Immune Defic Syndr. 2018;78:125–135. doi:10.1097/QAI.0000000000001660
   PubMed Web of Science ®Google Scholar
• Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (azt) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (hiv) infection. A double-blind, placebo-controlled trial. The aids clinical trials group. Ann Intern Med. 1990;112:727–737. doi:10.7326/0003-4819-112-10-727
   PubMed Web of Science ®Google Scholar
• Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with sars-cov-2 infection. Eur Respir J. 2020;56:2000799. doi:10.1183/13993003.00799-2020
   PubMed Web of Science ®Google Scholar
• Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of mers-cov infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904–1913. doi:10.1093/infdis/jiv392
   PubMed Web of Science ®Google Scholar
• Lecronier M, Beurton A, Burrel S, et al. Comparison of hydroxychloroquine, lopinavir/ ritonavir,and standard of care in critically ill patients with sars-cov-2 pneumonia: an opportunistic retrospective analysis. Crit Care. 2020;24:418. doi:10.1186/s13054-020-03117-9
   PubMed Web of Science ®Google Scholar
• Jang Y, Shin JS, Yoon YS, et al. Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function. J Virol. 2018;92:e01441. doi:10.1128/JVI.01441-18
   PubMed Web of Science ®Google Scholar
• Neri-Bazan RM, Garcia-Machorro J, Mendez-Luna D, et al. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza a virus h1n1. Eur J Med Chem. 2017;128:154–167. doi:10.1016/j.ejmech.2017.01.039
   PubMed Web of Science ®Google Scholar
• Todt D, Walter S, Brown RJ, Steinmann E. Mutagenic effects of ribavirin on hepatitis e virus-viral extinction versus selection of fitness-enhancing mutations. Viruses. 2016;8:283. doi:10.3390/v8100283
   PubMed Web of Science ®Google Scholar
• Avataneo V, de Nicolo A, Cusato J, et al. Development and validation of a uhplc-ms/ms method for quantification of the prodrug remdesivir and its metabolite gs-441524: a tool for clinical pharmacokinetics of sars-cov-2/covid-19 and ebola virus disease. J Antimicrob Chemother. 2020;75:1772–1777. doi:10.1093/jac/dkaa152
   PubMed Web of Science ®Google Scholar
• Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening rna virus infections. Pharmacol Ther. 2020;209:107512. doi:10.1016/j.pharmthera.2020.107512
   PubMed Web of Science ®Google Scholar
• Pagadala NS. Azt acts as an anti-influenza nucleotide triphosphate targeting the catalytic site of a/pr/8/34/h1n1 rna dependent rna polymerase. J Comput Aided Mol Des. 2019;33:387–404. doi:10.1007/s10822-019-00189-w
   PubMedGoogle Scholar
• Bertoletti N, Chan AH, Schinazi RF, Yin YW, Anderson KS. Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by hiv-1 reverse transcriptase: first crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Sci. 2019;28:1664–1675. doi:10.1002/pro.3681
   PubMed Web of Science ®Google Scholar
• Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis b infection in adults. Expert Rev Gastroenterol Hepatol. 2016;10:177–186. doi:10.1586/17474124.2016.1125781
   PubMed Web of Science ®Google Scholar
• Han Y, Pham HT, Xu H, Quan Y, Mesplede T. Antimalarial drugs and their metabolites are potent zika virus inhibitors. J Med Virol. 2019;91:1182–1190. doi:10.1002/jmv.25440
   PubMed Web of Science ®Google Scholar
• Chen Y, Ke M, Xu J, Lin C. Simulation of the pharmacokinetics of oseltamivir and its active metabolite in normal populations and patients with hepatic cirrhosis using physiologically based pharmacokinetic modeling. AAPS PharmSciTech. 2020;21:98. doi:10.1208/s12249-020-1638-y
   PubMedGoogle Scholar
• Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57:1743–1755. doi:10.1128/AAC.02282-12
   PubMed Web of Science ®Google Scholar
• Joshy KS, Susan MA, Snigdha S, Nandakumar K, Laly AP, Sabu T. Encapsulation of zidovudine in pf-68 coated alginate conjugate nanoparticles for anti-hiv drug delivery. Int J Biol Macromol. 2018;107:929–937. doi:10.1016/j.ijbiomac.2017.09.078
   PubMed Web of Science ®Google Scholar
• van Waterschoot RAB, Ter Heine R, Wagenaar E, et al. Effects of cytochrome p450 3a (cyp3a) and the drug transporters p-glycoprotein (mdr1/abcb1) and mrp2 (abcc2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010;160:1224–1233. doi:10.1111/j.1476-5381.2010.00759.x
   PubMed Web of Science ®Google Scholar
• Abd-Rabou AA, Bharali DJ, Mousa SA. Viramidine-loaded galactosylated nanoparticles induce hepatic cancer cell apoptosis and inhibit angiogenesis. Appl Biochem Biotechnol. 2020;190:305–324. doi:10.1007/s12010-019-03090-2
   PubMed Web of Science ®Google Scholar
• Patel BK, Parikh RH, Patel N. Targeted delivery of mannosylated-plga nanoparticles of antiretroviral drug to brain. Int J Nanomedicine. 2018;13:97–100. doi:10.2147/IJN.S124692
   PubMedGoogle Scholar
• Zhong J, Xia Y, Hua L, et al. Functionalized selenium nanoparticles enhance the anti-ev71 activity of oseltamivir in human astrocytoma cell model. Artif Cells Nanomed Biotechnol. 2019;47:3485–3491. doi:10.1080/21691401.2019.1640716
   PubMed Web of Science ®Google Scholar
• Yadavalli T, Ames J, Agelidis A, et al. Drug-encapsulated carbon (decon): a novel platform for enhanced drug delivery. Sci Adv. 2019;5:eaax0780. doi:10.1126/sciadv.aax0780
   PubMedGoogle Scholar
• Levy GA, Adamson G, Phillips MJ, et al. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology. 2006;43:581–591. doi:10.1002/hep.21072
   PubMedGoogle Scholar
• Giesler KE, Marengo J, Liotta DC. Reduction sensitive lipid conjugates of tenofovir: synthesis, stability, and antiviral activity. J Med Chem. 2016;59:7097–7110. doi:10.1021/acs.jmedchem.6b00428
   PubMedGoogle Scholar
• Lin CC, Yeh LT, Luu T, Lourenco D, Lau JY. Pharmacokinetics and metabolism of [(14)c]ribavirin in rats and cynomolgus monkeys. Antimicrob Agents Chemother. 2003;47:1395–1398. doi:10.1128/AAC.47.4.1395-1398.2003
   PubMed Web of Science ®Google Scholar
• Gowen BB, Sefing EJ, Westover JB, et al. Alterations in favipiravir (t-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121:132–137. doi:10.1016/j.antiviral.2015.07.003
   PubMed Web of Science ®Google Scholar
• Kumar P, Lakshmi YS, C. B, Golla K, Kondapi AK. Improved safety, bioavailability and pharmacokinetics of zidovudine through lactoferrin nanoparticles during oral administration in rats. PLoS One. 2015;10:e0140399. doi:10.1371/journal.pone.0140399
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kandikere V, Komarneni P, et al. Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study. Biomed Chromatogr. 2012;26:1472–1481. doi:10.1002/bmc.2718
   PubMedGoogle Scholar
• Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm. 2012;39:733–743. doi:10.3109/03639045.2012.694889
   PubMedGoogle Scholar
• Ho MJ, Lee DR, Im SH, et al. Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. Int J Pharm. 2018;543:52–59. doi:10.1016/j.ijpharm.2018.03.042
   PubMedGoogle Scholar
• Djekic L, Janković J, Rašković A, Primorac M. Semisolid self-microemulsifying drug delivery systems (smeddss): effects on pharmacokinetics of acyclovir in rats. Eur J Pharm Sci. 2018;121:287–292. doi:10.1016/j.ejps.2018.06.005
   PubMedGoogle Scholar
• Ravi PR, Vats R, Dalal V, Murthy AN. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J Pharm Pharmacol. 2014;66:912–926. doi:10.1111/jphp.12217
   PubMed Web of Science ®Google Scholar
• Joshi G, Kumar A, Sawant K. Bioavailability enhancement, caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded plga nanoparticles. Drug Deliv. 2016;23:3492–3504. doi:10.1080/10717544.2016.1199605
   PubMed Web of Science ®Google Scholar
• Islam MS, Reineke J, Kaushik R, et al. Bioadhesive food protein nanoparticles as pediatric oral drug delivery system. ACS Appl Mater Interfaces. 2019;11:18062–18073. doi:10.1021/acsami.9b00152
   PubMedGoogle Scholar
• Lei M, Gan W, Sun Y. Hplc-ms/ms analysis of peramivir in rat plasma: elimination of matrix effect using the phospholipid-removal solid-phase extraction method. Biomed Chromatogr. 2018;32:e4103. doi:10.1002/bmc.4103
   Google Scholar
• Koshimichi H, Ishibashi T, Wajima T. Population pharmacokinetics of baloxavir marboxil in japanese pediatric influenza patients. J Pharm Sci. 2019;108:3112–3117. doi:10.1016/j.xphs.2019.04.010
   PubMedGoogle Scholar
• Kropeit D, Scheuenpflug J, Erb-Zohar K, et al. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol. 2017;83:1944–1953. doi:10.1111/bcp.13292
   PubMed Web of Science ®Google Scholar
• Solórzano R, Tort O, García-Pardo J, et al. Versatile iron–catechol-based nanoscale coordination polymers with antiretroviral ligand functionalization and their use as efficient carriers in hiv/aids therapy. Biomater Sci. 2019;7:178–186. doi:10.1039/C8BM01221K
   Google Scholar
• Abdelbary GA, Amin MM, Zakaria MY, El Awdan SA. Adefovir dipivoxil loaded proliposomal powders with improved hepatoprotective activity: formulation, optimization, pharmacokinetic, and biodistribution studies. J Liposome Res. 2017;28:259–274. doi:10.1080/08982104.2017.1363228
   PubMedGoogle Scholar
• Gourdon B, Chemin C, Moreau A, et al. Functionalized pla-peg nanoparticles targeting intestinal transporter pept1 for oral delivery of acyclovir. Int J Pharm. 2017;529:357–370. doi:10.1016/j.ijpharm.2017.07.024
   PubMedGoogle Scholar
• Mao Y, Feng S, Li S, et al. Chylomicron-pretended nano-bio self-assembling vehicle to promote lymphatic transport and galts target of oral drugs. Biomaterials. 2019;188:173–186. doi:10.1016/j.biomaterials.2018.10.012
   PubMed Web of Science ®Google Scholar
• Ravi PR, Vats R, Balija J, Adapa SP, Aditya N. Modified pullulan nanoparticles for oral delivery of lopinavir: formulation and pharmacokinetic evaluation. Carbohydr Polym. 2014;110:320–328. doi:10.1016/j.carbpol.2014.03.099
   PubMed Web of Science ®Google Scholar
• Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018;17:559–587.
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Fogagnolo M, Ferraro L, et al. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. Eur J Pharm Biopharm. 2019;144:91–100. doi:10.1016/j.ejpb.2019.09.008
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2). Clin Infect Dis. 2020;71:732–739. doi:10.1093/cid/ciaa237
   PubMed Web of Science ®Google Scholar
• Zhong M, Feng Y, Liao H, et al. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. Pharm Res. 2014;31:2857–2867. doi:10.1007/s11095-014-1382-7
   PubMed Web of Science ®Google Scholar
• Wannachaiyasit S, Chanvorachote P, Nimmannit U. A novel anti-hiv dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. AAPS PharmSciTech. 2008;9:840–850. doi:10.1208/s12249-008-9122-0
   PubMedGoogle Scholar
• Senanayake TH, Gorantla S, Makarov E, Lu Y, Warren G, Vinogradov SV. Nanogel-conjugated reverse transcriptase inhibitors and their combinations as novel antiviral agents with increased efficacy against hiv-1 infection. Mol Pharm. 2015;12:4226–4236. doi:10.1021/acs.molpharmaceut.5b00424
   PubMedGoogle Scholar
• Dutta L, Mukherjee B, Chakraborty T, et al. Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain. Drug Deliv. 2018;25:504–516. doi:10.1080/10717544.2018.1435749
   PubMed Web of Science ®Google Scholar
• Li CL, Hsieh CH, Tsai TH. Preclinical pharmacokinetics of lamivudine and its interaction with schisandra chinensis extract in rats. ACS Omega. 2020;5:1997–2004. doi:10.1021/acsomega.9b03922
   PubMedGoogle Scholar
• Ayoub MM, Elantouny NG, El-Nahas HM, Ghazy FES. Injectable plga adefovir microspheres; the way for long term therapy of chronic hepatitis-b. Eur J Pharm Sci. 2018;118:24–31. doi:10.1016/j.ejps.2018.03.016
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang A, Wang H, et al. Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-b: preparation and in vitro and in vivo evaluation. Int J Pharm. 2019;560:27–34. doi:10.1016/j.ijpharm.2019.01.052
   PubMedGoogle Scholar
• Perazzolo S, Shireman LM, McConnachie LA, et al. Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-hiv drug combination tlc-art 101. J Pharm Sci. 2020;109:1789–1801. doi:10.1016/j.xphs.2020.01.016
   PubMed Web of Science ®Google Scholar
• Giuliani A, Balducci AG, Zironi E, et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv. 2018;25:376–387. doi:10.1080/10717544.2018.1428242
   PubMed Web of Science ®Google Scholar